GlobeNewswire: Vital Therapies, Inc. Contains the last 10 of 84 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:48:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/04/10/1802326/0/en/Vital-Therapies-Inc-Announces-Filing-of-its-Form-10-Q-for-the-Quarter-Ended-March-31-2019.html?f=22&fvtc=4&fvtv=22510Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 20192019-04-10T20:35:00Z<![CDATA[SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to facilitate the closing of the Company’s transaction with Immunic AG. As previously announced, the transaction has been approved by the stockholders of the Company and is expected to be consummated by mid-April. In connection with the closing of the transaction, Vital Therapies will change its name to Immunic, Inc. and the Company’s shares are expected to trade on The Nasdaq Stock Market under the symbol “IMUX”.]]>https://www.globenewswire.com/news-release/2019/04/04/1797376/0/en/Vital-Therapies-Inc-Announces-Stockholder-Approval-of-Business-Combination-with-Immunic-AG.html?f=22&fvtc=4&fvtv=22510Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG2019-04-04T20:07:00Z<![CDATA[SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held earlier today. Approximately 98.82% of the shares voted at the special stockholder meeting voted in favor of the Exchange Agreement proposal, with each of the other related proposals also receiving sufficient votes for approval.]]>https://www.globenewswire.com/news-release/2019/03/27/1773722/0/en/Vital-Therapies-Reminds-Stockholders-to-Vote-For-the-Proposed-Business-Combination-With-Immunic-AG.html?f=22&fvtc=4&fvtv=22510Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG2019-03-27T10:00:00Z<![CDATA[SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) would like to thank its stockholders for their support of the proposed business combination with Immunic AG and remind those stockholders that have not yet voted to vote without delay “FOR” the business combination and the other proposals in the Company’s proxy statement/prospectus for the special meeting of its stockholders to be held on April 4, 2019 at 9:00 a.m. Pacific Time.]]>https://www.globenewswire.com/news-release/2019/03/25/1759913/0/en/Leading-Independent-Proxy-Advisory-Firms-ISS-and-Glass-Lewis-Recommend-Vital-Therapies-Stockholders-Vote-FOR-the-Proposed-Business-Transaction-With-Immunic-AG-and-All-the-Related-P.html?f=22&fvtc=4&fvtv=22510Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals2019-03-25T09:00:00Z<![CDATA[SAN DIEGO, March 25, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Vital Therapies stockholders vote “FOR” the proposed business combination with Immunic AG and the related proposals in the Company’s proxy statement/prospectus for the special meeting of its stockholders to be held on April 4, 2019 at 9:00 a.m. Pacific Time.]]>https://www.globenewswire.com/news-release/2019/03/04/1747571/0/en/Vital-Therapies-Announces-2018-Financial-Results.html?f=22&fvtc=4&fvtv=22510Vital Therapies Announces 2018 Financial Results2019-03-04T21:10:00Z<![CDATA[SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the year ended December 31, 2018.]]>https://www.globenewswire.com/news-release/2019/01/07/1680992/0/en/Vital-Therapies-and-Immunic-Therapeutics-Announce-Transaction-to-Create-Leading-Inflammatory-and-Autoimmune-Disease-Company.html?f=22&fvtc=4&fvtv=22510Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company2019-01-07T09:00:00Z<![CDATA[– Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets –]]>https://www.globenewswire.com/news-release/2018/11/07/1647555/0/en/Vital-Therapies-Announces-Third-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=22510Vital Therapies Announces Third Quarter 2018 Financial Results2018-11-07T23:20:35Z<![CDATA[SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the third quarter ended September 30, 2018.]]>https://www.globenewswire.com/news-release/2018/10/11/1620045/0/en/Vital-Therapies-Provides-Strategic-Update.html?f=22&fvtc=4&fvtv=22510Vital Therapies Provides Strategic Update2018-10-11T13:27:41Z<![CDATA[SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced updates on the Company’s ongoing strategy to preserve its cash and maximize shareholder value. To further that objective, the Company has retained Ladenburg Thalmann & Co. Inc. as its strategic financial advisor to assist in the review of the Company's business and assets and exploration of strategic opportunities for enhancing stockholder value, including the potential sale or merger of the Company. The Company cannot guarantee that this process will culminate in a transaction.]]>https://www.globenewswire.com/news-release/2018/09/29/1587373/0/en/Vital-Therapies-to-Present-at-the-19th-International-Liver-Support-Meeting.html?f=22&fvtc=4&fvtv=22510Vital Therapies to Present at the 19th International Liver Support Meeting2018-09-29T14:00:09Z<![CDATA[SAN DIEGO, Sept. 29, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that additional data from its VTL-308 clinical trial will be presented today at the 19th International Liver Support Meeting in Rostock-Warnemunde, Germany. The presentation, titled "Update on ELAD Study VTL-308", will be made by Nikolaos T. Pyrsopoulos, M.D., Ph.D., Professor and Chief, Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School.]]>https://www.globenewswire.com/news-release/2018/09/12/1569553/0/en/Vital-Therapies-Announces-That-Topline-Results-of-VTL-308-Fail-to-Achieve-Primary-and-Secondary-Endpoints-of-Improvement-in-Survival.html?f=22&fvtc=4&fvtv=22510Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival2018-09-12T09:00:00Z<![CDATA[SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that, while there was a numerical improvement in survival in the ELAD-treated group between three months and one year following randomization, the VTL-308 study failed to meet the primary endpoint of a significant improvement in overall survival through at least 91 days assessed using the Kaplan Meier statistical method. The secondary endpoint of proportion of survivors at study day 91 also showed no statistically significant difference between the groups.]]>